Saturday 17 October 2026
Export DSGN’s income statement to Excel — free account
Design Therapeutics, Inc.
DSGN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 5.88% and free cash flow fell 7.00%, each against the same quarter a year earlier.
10.31
0.17
−1.62%
Follow DSGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (34.13%) | (31.26%) | (30.70%) | (29.83%) |
+8 more TTM periods Free account |
|
| (32.33%) | (29.80%) | (29.18%) | (28.49%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(35.14%) | (32.03%) | (32.97%) | (33.90%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.88) | (0.88) | (0.95) | (0.92) | |
Free Cash Flow |
(55.22) | (54.00) | (54.55) | (52.41) | |
Capital Expenditures |
(0.14) | — | (0.19) | (0.16) | |
| Other line items | |||||
Cash ROIC |
(13.49%) | (12.25%) | (12.62%) | (12.92%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 0.77 | 0.78 | 0.77 | |
Depreciation/Fixed assets |
(1.18) | (2.09) | (2.68) | (3.23) | |
Capex/Depreciation |
0.17 | 0.00 | 0.07 | 0.04 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.88) | (0.88) | (0.95) | (0.92) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates